Directorios

Actelion response on recent shareholder communication

Actelion and GSK Discontinue Clinical Development of Almorexant

Actelion Ltd (SIX: ATLN) and GlaxoSmithKline (GSK) today announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued. This decision follows a review of data from additional clinical studies, which were conducted to further establish the clinical profile of almorexant, including the tolerability profile.

Actelion to Present at the 29th Annual J.P. Morgan Healthcare Conference

Actelion Ltd (SIX: ATLN) Actelion Ltd (SIX: ATLN) announced today that Jean-Paul Clozel, M.D., Chief Executive Officer of Actelion, will present at the upcoming J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 10.30 a.m. Pacific time / 7.30 p.m. Swiss time at the Westin St. Francis Hotel in San Francisco, CA

Actelion announces change in its Board of Directors

Actelion Ltd (SIX: ATLN) announced today that Dr. Elias Zerhouni has resigned from Actelion's Board of Director at the end of 2010. Dr. Zerhouni will focus on his new role as President, Global Research and Development at Sanofi-aventis, an executive function he is assuming as of the beginning of 2011.